Advanced Science

Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections

Retrieved on: 
목요일, 3월 14, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Infection, Bronchiolitis, Risk, Viral load, COVID-19, Inflammation, Lung, PIV, SARS-CoV-2, RSV, IND, Antibody, Omicron, Biological engineering, Translational medicine, Vaccine, Animal, Advanced Science

Inhalon Biopharma (Inhalon), a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections, today announced the publication of preclinical data showcasing the advantages and efficacy of its “muco-trapping” technology in animal models of respiratory syncytial virus (RSV) and SARS-CoV-2 infections.

Key Points: 
  • Inhalon Biopharma (Inhalon), a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections, today announced the publication of preclinical data showcasing the advantages and efficacy of its “muco-trapping” technology in animal models of respiratory syncytial virus (RSV) and SARS-CoV-2 infections.
  • “Inhalon’s approach rethinks the use of antibodies for the treatment of acute respiratory infections by delivering antibodies directly to the site of the infection,” said John Whelan, president and chief executive officer, Inhalon Biopharma.
  • “Our studies in Advanced Science and in Bioengineering and Translational Medicine demonstrate the exceptional effectiveness of our inhaled antibody platform, which offers the potential to treat a wide array of acute respiratory infections.
  • With the support of the USAMRDC, Inhalon has begun preclinical activities and manufacturing to advance this candidate into the clinic in 2025.

A faster, more efficient imaging system for nanoparticles

Retrieved on: 
화요일, 1월 30, 2024
Nanoparticle, Research, Nanomedicine, Temperature, Photon, Science, Tissue, Cancer, SWIR, Advanced Science, Noetics, INRS, Doctor of Philosophy, Metabolism, Cell, Medical imaging

A new technique developed at INRS pushes back some of the limits of the infrared imaging of rare-earth doped nanoparticles.

Key Points: 
  • A new technique developed at INRS pushes back some of the limits of the infrared imaging of rare-earth doped nanoparticles.
  • It consists of a high-precision, short-wave infrared imaging technique capable of capturing the photoluminescence lifetimes of rare-earth doped nanoparticles in the micro- to millisecond range.
  • What's more, the photoluminescence lifetime of nanoparticles doped with these ions has the advantage of being minimally affected by external conditions.
  • Finally, in fundamental science, these unprecedented results will allow scientists to synthesize rare-earth nanoparticles with even more interesting optical properties.

AI for Life Sciences concludes its first hackathon aimed at driving innovation in life science domains

Retrieved on: 
월요일, 1월 29, 2024
Manna, Student, University, Research, University of Vienna, Biodiversity, Health, FLSmidth, Multimedia, Intelligence, Science, AI, Kyoto University, Microbiology, MIT License, Soil health, Advanced Science, Doctor of Philosophy, Organization, Prize, Soil, BSD licenses, Medical device

VIENNA, Jan. 29, 2024 /PRNewswire/ -- AI for Life Sciences successfully hosted its first hackathon event in December 2023 where teams from around the world competed in a virtual coding challenge.

Key Points: 
  • VIENNA, Jan. 29, 2024 /PRNewswire/ -- AI for Life Sciences successfully hosted its first hackathon event in December 2023 where teams from around the world competed in a virtual coding challenge.
  • AI for Life Sciences connects AI enthusiasts with organizations interested in exploring how to apply AI to use cases in various life sciences domains.
  • By working together with Gradient Zero to set the first AI for Life Sciences challenge, we were able to tap into this potential.
  • To learn more about AI for Life Sciences and register for the next challenge, visit ai4lifesciences.com .

AI for Life Sciences concludes its first hackathon aimed at driving innovation in life science domains

Retrieved on: 
월요일, 1월 29, 2024
Manna, Student, University, Research, University of Vienna, Biodiversity, Health, FLSmidth, Intelligence, Science, AI, Kyoto University, Microbiology, MIT License, Soil health, Advanced Science, Doctor of Philosophy, Organization, Prize, Soil, BSD licenses, Medical device

VIENNA, Jan. 29, 2024 /PRNewswire/ -- AI for Life Sciences successfully hosted its first hackathon event in December 2023 where teams from around the world competed in a virtual coding challenge.

Key Points: 
  • VIENNA, Jan. 29, 2024 /PRNewswire/ -- AI for Life Sciences successfully hosted its first hackathon event in December 2023 where teams from around the world competed in a virtual coding challenge.
  • AI for Life Sciences connects AI enthusiasts with organizations interested in exploring how to apply AI to use cases in various life sciences domains.
  • By working together with Gradient Zero to set the first AI for Life Sciences challenge, we were able to tap into this potential.
  • To learn more about AI for Life Sciences and register for the next challenge, visit ai4lifesciences.com .

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024

Retrieved on: 
목요일, 8월 10, 2023
COPD, Advanced Science, UNO, Conference call, Spectrum, Calendar, DSM-IV codes, NOS1, Avenue Capital Group, Trial of the century, Hospital, NTM, Nontuberculous mycobacteria, Patient, Atmosphere of Earth, ASD, VCAP, Research, FDA, Conference, Pneumonia, Vaccine, Pharmaceutical industry, Cryptocurrency

“We concluded the first quarter of our fiscal year 2024 with LungFit PH adopted as the nitric oxide system of choice at several hospitals in the United States.

Key Points: 
  • “We concluded the first quarter of our fiscal year 2024 with LungFit PH adopted as the nitric oxide system of choice at several hospitals in the United States.
  • Our commercial team has implemented training programs and support at each of these hospitals, and report that LungFit PH has been well received.
  • General and administrative expenses for the three months ended June 30, 2023 and June 30, 2022 were $10.9 million and $8.2 million, respectively.
  • As of June 30, 2023, the Company had cash, cash equivalents and marketable securities of $57.0 million and $2.7 million in restricted cash.

Crystal IS and Asahi Kasei Announce First 4-inch Aluminum Nitride Substrate

Retrieved on: 
수요일, 8월 9, 2023
Technology, Mobile, Wireless, Other Science, Research, Utilities, Alternative Energy, Energy, Automotive, Health, Satellite, General Health, Nanotechnology, Science, Telecommunications, General Automotive, Networks, Engineering, Hardware, Automotive Manufacturing, Electronic Design Automation, Aerospace, Manufacturing, Consumer Electronics, Aluminium nitride, Light-emitting diode, Advanced Science, Thermal conductivity, Crystal, UVC, Asahi Kasei, Multimedia, Boule (crystal), American Conference, Crystal growth, Conference, RF, Aluminium, Printed circuit board

Crystal IS, an Asahi Kasei company, today announced the successful production of a 4-inch (100 mm) diameter single-crystal aluminum nitride (AlN) substrate.

Key Points: 
  • Crystal IS, an Asahi Kasei company, today announced the successful production of a 4-inch (100 mm) diameter single-crystal aluminum nitride (AlN) substrate.
  • View the full release here: https://www.businesswire.com/news/home/20230809402685/en/
    Crystal IS 4-inch (100 mm) diameter bulk aluminum nitride substrate comparison.
  • “We are extremely excited to announce the achievement of a 4-inch bulk aluminum nitride substrate,” said Dr. Naohiro Kuze, Executive Fellow at the Research Laboratory of Advanced Science and Technology, Asahi Kasei.
  • For more information on Aluminum Nitride and Crystal IS products, visit cisuvc.com or contact [email protected] .

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

Retrieved on: 
목요일, 6월 22, 2023
COPD, Bronchiolitis, Advanced Science, Autism spectrum, Conference call, Calendar, Nitric oxide, DSM-IV codes, GAAP, Research, NOS1, Avenue Capital Group, PPHN, NO, Hospital, NTM, Nontuberculous mycobacteria, Patent, Patient, ASD, VCAP, Spectrum, Delivery, BRO, FDA, Conference, Pharmaceutical industry, Cryptocurrency, Cancer, Circassia

Selling, general and administrative expenses for the fiscal year ended March 31, 2023, increased to $34.7 million, compared with $18.4 million for the fiscal year ended March 31, 2022.

Key Points: 
  • Selling, general and administrative expenses for the fiscal year ended March 31, 2023, increased to $34.7 million, compared with $18.4 million for the fiscal year ended March 31, 2022.
  • As a reminder, the Company paid $2.5 million to Circassia in the 2nd fiscal quarter of 2023, we have another $3.5 million to pay in the 2nd fiscal quarter of 2024 with the final $4.5 million not due until the 2nd quarter of fiscal 2025.
  • Other income and expense was a $7.3 million loss for the fiscal year ended March 31, 2023, compared with a $3.4 million loss for the fiscal year ended March 31, 2022.
  • The increase of $3.9 million was primarily due to a non-product related legal matter that was resolved in the fourth fiscal quarter of 2023.

Gwangju Institute of Science and Technology Researchers Enhance Electron-Phonon Coupling Strength in Low-Dimensional Strontium Ruthenate

Retrieved on: 
목요일, 6월 22, 2023
Electron, Gwangju Institute of Science and Technology, Volume Ten, Advanced Science, 3D, Light, Phonon, 2D, SRO, Engineering, Motivation, Physics, Periodicity, Ceramic

GWANGJU CITY, South Korea, June 22, 2023 /PRNewswire/ -- Electrons inside crystals interact closely with phonons, defined as the discrete unit of crystal vibrations. The electron–phonon coupling strength is an important fundamental physical quantity in solid state physics, determining electrodynamic behaviors and correlated functionalities of a material. This, in turn, makes for interesting material properties with advanced applications. However, the coupling strength is typically considered an intrinsic material property without any provision for controlling it for desired applications.

Key Points: 
  • The electron–phonon coupling strength is an important fundamental physical quantity in solid state physics, determining electrodynamic behaviors and correlated functionalities of a material.
  • However, the coupling strength is typically considered an intrinsic material property without any provision for controlling it for desired applications.
  • In their study, the researchers demonstrated an atomic-scale engineering of the electron–phonon coupling strength in synthetic strontium ruthenate/strontium titanate (SRO/STO) superlattices (a periodic structure of layers of two materials).
  • Remarkably, a reduction in the dimensionality from 3D (bulk) to quasi-2D led to a 300-fold increase in the electron–phonon coupling strength.

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

Retrieved on: 
목요일, 6월 15, 2023
Al-Quds, Medical school, HUJI, Nitric oxide, Wolf Foundation, NOS1, Doctor of Philosophy, DSM-IV codes, NO, Journal, Patient, Society, Phenotype, Male, Human, Hebrew University of Jerusalem, Advanced Science, Research, SNAP, FDA, Conference, Neuropharmacology, Conference call, Cancer, MIT, Biomarker, Cell, Publication, ASD, Webcast, LTD, Faculty, Partnership, Cell death, Spectrum, Urinary tract infection, SHANK3, Atmosphere of Earth, University of Toronto Faculty of Medicine, Yissum Research Development Company of the Hebrew University, Mouse, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, M1, Psychiatry, Pharmacy, Tel Aviv University, Medicine

GARDEN CITY, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to license the commercial rights for multiple neuronal nitric oxide synthase (nNOS) inhibitor candidates, currently being developed for the treatment of autism spectrum disorder (ASD) and other neurological conditions. There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ASD.

Key Points: 
  • There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ASD.
  • The partial inhibition of nNOS reduces nitrosative stress biomarkers and reverses the molecular, synaptic and behavioral ASD-associated phenotypes.
  • Dr. Amal is an Assistant Professor at the Institute for Drug Research, Faculty of Medicine at the Hebrew University of Jerusalem.
  • He began his academic journey at the age of seventeen, with a degree in Pharmacy, from the Hebrew University.

By Mimicking Nature, Scientists Build a Better Artificial Lung

Retrieved on: 
화요일, 5월 30, 2023
Fort Detrick, Heart, Respiratory failure, American Society for Artificial Internal Organs, Advanced Science, Bleeding, Bed, Code, Oxygen, Extracorporeal membrane oxygenation, Critical care, ECMO, Research, Coagulopathy, Biomaterial, Carbon, Bangladesh Technical Education Board, Assistant, Lung, Microfluidics, Acquisition, Animal, Patient, ECLS, Blood, Department of Defense Serum Repository, Draper, Paper, Nursing care plan, ICU, Human body, Trauma, Society, Assistant Secretary of Defense for Health Affairs, United States Department of Agriculture, Pneumonia, Safety, AREVA, Medical device, Medical imaging, Defense

CAMBRIDGE, Mass., May 30, 2023 /PRNewswire-PRWeb/ -- A mechanical device for oxygenating blood outside the human body, essentially functioning as an artificial lung, is taking a leap forward fifty years after its debut. The original device in clinical use today, called ECMO, which stands for extracorporeal membrane oxygenation, has been reimagined by bioengineers at Draper who took their cues from the way the human body oxygenates blood in the branching circulatory system.

Key Points: 
  • By mimicking blood flow patterns in the human body, engineers improve the safety and efficacy of artificial lungs, a potential benefit to critical care patients and combat casualties.
  • CAMBRIDGE, Mass., May 30, 2023 /PRNewswire-PRWeb/ -- A mechanical device for oxygenating blood outside the human body, essentially functioning as an artificial lung, is taking a leap forward fifty years after its debut.
  • Critical care patients such as premature infants, transplant and pneumonia patients and others suffering respiratory failure and related conditions may benefit, he added.
  • Opinions, interpretations, conclusions, and recommendations contained herein are those of the author(s) and are not necessarily endorsed by the Department of Defense.